100% agreed on all points, and for the sake of it, these are my...

100% agreed on all points, and for the sake of it, these are my guestimates for each key point you mention:

1. 22c immediately before the January FDA review-duration announcement, and reaching 27-32c nearer the FDA approval date (whenever that be)
2. I'll give a couple of cents to the next Kaken report, but where the SP will be at, depends entirely on whether we're waiting 2 or 6 months
3. FDA approval - bump to 45c
4. I don't give much to Sofdra hitting the market - that is widely anticipated already. It's just the next logical step, so maybe a cent or two.
5. Agreed that first Sofdra sales figures are another pivotal moment. If they are indicate quick takeup in an expansive market, look out! In that case I reckon we could reach 80c, perhaps more. If they are less than impressive, expect a slight retraction temporarily, until the 2nd quarter of sales reveals strong growth.

Definitely the game changes if one or two BP start sniffing around. I still have hope that there is one waiting in the wings for the FDA approval before it being announced they are buying BOT!

I have been surprised at how underwhelming the market has been toward BOT - not sure if it is waiting confirmation that the product will make worthwhile sales, or if it's just the economic times and lack of love for bio in 2023.